PE20070181A1 - DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA - Google Patents
DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASAInfo
- Publication number
- PE20070181A1 PE20070181A1 PE2006000895A PE2006000895A PE20070181A1 PE 20070181 A1 PE20070181 A1 PE 20070181A1 PE 2006000895 A PE2006000895 A PE 2006000895A PE 2006000895 A PE2006000895 A PE 2006000895A PE 20070181 A1 PE20070181 A1 PE 20070181A1
- Authority
- PE
- Peru
- Prior art keywords
- alkylene
- alkyl
- halogen
- isoquinolin
- rho
- Prior art date
Links
- 102000000568 rho-Associated Kinases Human genes 0.000 title abstract 2
- 108010041788 rho-Associated Kinases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
Abstract
SE REFIERE A COMPUESTOS DE ISOQUINOLONA O ISOQUINOLINAS SUSTITUIDOS CON 6-CICLOHEXILAMINAS, DE FORMULAS (I) O (I'), EN DONDE R1 ES H, ALQUILO(C1-C6), ALQUENILO O ALQUINILO(C2-C6), [ALQUILENO(C1-C6)0-1-CICLOALQUILO(C3-C8), ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), [ALQUILENO(C1-C6)]0-1-R', ENTRE OTROS; R3 ES H, HALOGENO, CN, ENTRE OTROS; R4 ES H, HALOGENO, HIDROXI, ENTRE OTROS; R5 ES H, HALOGENO, NO2, ENTRE OTROS; R6 Y R6' SON INDEPENDIENTEMENTE H, R', ALQUILO(C1-C8), ALQUILENO(C1-C6)-O-ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ALQUILENO(C1-C4)-HETEROCICLILO, ENTRE OTROS; R7 Y R8 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS; R9 ES HALOGENO O ALQUILO(C1-C6); n ES 0,1,2,3 o 4; L ES O o O-ALQUILENO(C1-C6). SON PREFERIDOS: 6-(CIS-4-DIETILAMINO-CICLOHEXILOXI)-7-METIL-2H-ISOQUINOLIN-1-ONA, 6-(CIS-4-ISOPROPILAMINO-CICLOHEXILOXI)-7-METIL-2H-ISOQUINOLIN-1-ONA, 2-(TRANS-4-METOXI-BENCIL9-6-(4-METILANIMO-CICLOHEXILOXI)-2H-ISOQUINOLIN-1-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIETO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA Rho-QUINASA Y/O SOBRE LA FOSFORILACION MEDIADA POR LA Rho.QUINASA DE LA FOSFATASA DE LA CADENA LIGERA DE MIOSINA, Y SON UTILES PARA EL TRATAMIENTO HIPERTENSION OCULAR, FIBROSIS HEPATICA, DOLOR NEUROPATICO, SINDROME METABOLICO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05016153 | 2005-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070181A1 true PE20070181A1 (es) | 2007-03-07 |
Family
ID=35115842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000895A PE20070181A1 (es) | 2005-07-26 | 2006-07-25 | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA |
Country Status (37)
Country | Link |
---|---|
US (2) | US8609691B2 (es) |
EP (1) | EP1912949B1 (es) |
JP (1) | JP5049970B2 (es) |
KR (1) | KR101336678B1 (es) |
CN (1) | CN101228132B (es) |
AR (1) | AR057082A1 (es) |
AT (1) | ATE521595T1 (es) |
AU (1) | AU2006274246B2 (es) |
BR (1) | BRPI0614063A2 (es) |
CA (1) | CA2615663C (es) |
CR (1) | CR9604A (es) |
CY (1) | CY1112085T1 (es) |
DK (1) | DK1912949T3 (es) |
DO (1) | DOP2006000177A (es) |
EC (1) | ECSP088136A (es) |
ES (1) | ES2372067T3 (es) |
GT (1) | GT200600327A (es) |
HK (1) | HK1123036A1 (es) |
HN (1) | HN2008000130A (es) |
HR (1) | HRP20110839T1 (es) |
IL (1) | IL188949A (es) |
MA (1) | MA29639B1 (es) |
MX (1) | MX2008000956A (es) |
MY (1) | MY146644A (es) |
NI (1) | NI200800024A (es) |
NO (1) | NO20080965L (es) |
NZ (1) | NZ565669A (es) |
PE (1) | PE20070181A1 (es) |
PL (1) | PL1912949T3 (es) |
PT (1) | PT1912949E (es) |
RS (1) | RS52241B (es) |
RU (1) | RU2440988C2 (es) |
SI (1) | SI1912949T1 (es) |
TN (1) | TNSN08038A1 (es) |
TW (1) | TWI412521B (es) |
WO (1) | WO2007012422A1 (es) |
ZA (1) | ZA200710952B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1899322E (pt) | 2005-06-28 | 2009-11-09 | Sanofi Aventis | Derivados de isoquinolina como inibidores de rho-cinase |
NI200800025A (es) | 2005-07-26 | 2009-03-03 | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa | |
ATE521595T1 (de) | 2005-07-26 | 2011-09-15 | Sanofi Sa | Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor |
US7893088B2 (en) * | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
ATE523493T1 (de) * | 2006-09-11 | 2011-09-15 | Organon Nv | 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate |
CA2673920C (en) * | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
MX2009005825A (es) | 2006-12-27 | 2009-06-16 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. |
JP5405314B2 (ja) * | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
CN101573354B (zh) | 2006-12-27 | 2014-02-12 | 塞诺菲-安万特股份有限公司 | 取代的异喹啉类及其作为Rho-激酶抑制剂的用途 |
SI2102164T1 (sl) | 2006-12-27 | 2011-03-31 | Sanofi Aventis | Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom |
CL2008000973A1 (es) | 2007-04-05 | 2009-01-02 | Astrazeneca Ab | Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma. |
JP5524071B2 (ja) * | 2007-10-24 | 2014-06-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト |
MX2010013974A (es) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Isoquinolinas e isoquinolinonas 6-sustituidas. |
RU2538588C2 (ru) * | 2008-06-24 | 2015-01-10 | Санофи-Авентис | ЗАМЕЩЕННЫЕ ИЗИХИНОЛИНЫ И ИЗОХИНОЛИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ |
DK2303845T3 (da) * | 2008-06-24 | 2013-12-16 | Sanofi Sa | Bi- og polycyklisk substitueret isoquinolin og bi- og polycykliske substituerede isoquinolinderivater som rho-kinasehæmmere |
KR101354763B1 (ko) | 2008-08-25 | 2014-01-22 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제 |
AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
EP3252050B1 (en) * | 2013-01-18 | 2020-02-26 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
CA2927567C (en) | 2013-10-18 | 2022-04-26 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
WO2015060373A1 (ja) * | 2013-10-23 | 2015-04-30 | 中外製薬株式会社 | キナゾリノンおよびイソキノリノン誘導体 |
FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
EP3294871A1 (en) | 2015-05-12 | 2018-03-21 | Platod | Combination of pharmacological and microfluidic features for improved platelets production |
US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
JP2019513804A (ja) | 2016-04-18 | 2019-05-30 | セルジーン クオンティセル リサーチ,インク. | 治療用化合物 |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
CA3102645A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
CN114874236B (zh) * | 2022-06-24 | 2023-05-05 | 中国工程物理研究院化工材料研究所 | 一种五元氮杂稠环骨架及其制备方法 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
EP0541559A1 (en) | 1990-07-31 | 1993-05-19 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
SI0956865T2 (sl) | 1996-08-12 | 2011-04-29 | Mitsubishi Pharma Corp | Zdravila, ki obsegajo inhibitor Rho-kinaze |
JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
EP1007525A1 (en) | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
MXPA02007036A (es) | 2000-01-20 | 2002-12-13 | Eisai Co Ltd | Compuesto de piperidina novedoso y composicion farmaceutica del mismo. |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
KR20050019918A (ko) * | 2002-07-22 | 2005-03-03 | 아사히 가세이 파마 가부시키가이샤 | 5-치환 이소퀴놀린 유도체 |
JPWO2004009555A1 (ja) * | 2002-07-22 | 2005-11-17 | 旭化成ファーマ株式会社 | 5−置換イソキノリン誘導体 |
JPWO2004024717A1 (ja) | 2002-09-12 | 2006-01-05 | 麒麟麦酒株式会社 | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 |
PT1603566E (pt) * | 2003-03-11 | 2009-04-27 | Novartis Ag | Utilização de derivados de isoquinolina para tratamento de cancro e de doenças relacionadas com map-cinase |
US20040225116A1 (en) | 2003-05-08 | 2004-11-11 | Payne Mark S. | Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids |
US20050014783A1 (en) | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
WO2005020081A2 (en) | 2003-08-22 | 2005-03-03 | 4Links Limited | Communication system using embedded synchronisation |
US7691879B2 (en) | 2003-09-23 | 2010-04-06 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
CN1856476A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉酮钾通道抑制剂 |
US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
EP1671962A1 (en) * | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
JP4969049B2 (ja) * | 2004-04-06 | 2012-07-04 | 株式会社アマダ | 曲げ加工装置 |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
EP1741525A1 (de) | 2005-07-06 | 2007-01-10 | Trumpf Werkzeugmaschinen GmbH + Co. KG | Vorrichtung zur Aufnahme von plattenförmigen Materialien |
NI200800025A (es) | 2005-07-26 | 2009-03-03 | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa | |
ATE521595T1 (de) | 2005-07-26 | 2011-09-15 | Sanofi Sa | Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor |
TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
JP4033221B2 (ja) | 2005-12-02 | 2008-01-16 | ダイキン工業株式会社 | 冷媒加熱装置 |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
CN101573354B (zh) | 2006-12-27 | 2014-02-12 | 塞诺菲-安万特股份有限公司 | 取代的异喹啉类及其作为Rho-激酶抑制剂的用途 |
SI2102164T1 (sl) | 2006-12-27 | 2011-03-31 | Sanofi Aventis | Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom |
-
2006
- 2006-07-20 AT AT06776307T patent/ATE521595T1/de active
- 2006-07-20 BR BRPI0614063-7A patent/BRPI0614063A2/pt active Search and Examination
- 2006-07-20 NI NI200800024A patent/NI200800024A/es unknown
- 2006-07-20 DK DK06776307.8T patent/DK1912949T3/da active
- 2006-07-20 RS RS20110494A patent/RS52241B/en unknown
- 2006-07-20 PL PL06776307T patent/PL1912949T3/pl unknown
- 2006-07-20 PT PT06776307T patent/PT1912949E/pt unknown
- 2006-07-20 CA CA2615663A patent/CA2615663C/en not_active Expired - Fee Related
- 2006-07-20 SI SI200631175T patent/SI1912949T1/sl unknown
- 2006-07-20 ES ES06776307T patent/ES2372067T3/es active Active
- 2006-07-20 EP EP06776307A patent/EP1912949B1/en active Active
- 2006-07-20 RU RU2008106926/04A patent/RU2440988C2/ru not_active IP Right Cessation
- 2006-07-20 MX MX2008000956A patent/MX2008000956A/es active IP Right Grant
- 2006-07-20 JP JP2008523189A patent/JP5049970B2/ja not_active Expired - Fee Related
- 2006-07-20 WO PCT/EP2006/007140 patent/WO2007012422A1/en active Application Filing
- 2006-07-20 KR KR1020087002147A patent/KR101336678B1/ko not_active IP Right Cessation
- 2006-07-20 NZ NZ565669A patent/NZ565669A/en not_active IP Right Cessation
- 2006-07-20 CN CN2006800271401A patent/CN101228132B/zh not_active Expired - Fee Related
- 2006-07-20 AU AU2006274246A patent/AU2006274246B2/en not_active Ceased
- 2006-07-24 MY MYPI20063516A patent/MY146644A/en unknown
- 2006-07-24 TW TW095126883A patent/TWI412521B/zh not_active IP Right Cessation
- 2006-07-24 GT GT200600327A patent/GT200600327A/es unknown
- 2006-07-25 PE PE2006000895A patent/PE20070181A1/es not_active Application Discontinuation
- 2006-07-25 DO DO2006000177A patent/DOP2006000177A/es unknown
- 2006-07-25 AR ARP060103200A patent/AR057082A1/es unknown
-
2007
- 2007-12-18 ZA ZA200710952A patent/ZA200710952B/xx unknown
- 2007-12-18 CR CR9604A patent/CR9604A/es not_active Application Discontinuation
-
2008
- 2008-01-21 MA MA30586A patent/MA29639B1/fr unknown
- 2008-01-22 IL IL188949A patent/IL188949A/en not_active IP Right Cessation
- 2008-01-25 EC EC2008008136A patent/ECSP088136A/es unknown
- 2008-01-25 US US12/019,799 patent/US8609691B2/en not_active Expired - Fee Related
- 2008-01-25 TN TNP2008000038A patent/TNSN08038A1/en unknown
- 2008-01-28 HN HN2008000130A patent/HN2008000130A/es unknown
- 2008-02-22 NO NO20080965A patent/NO20080965L/no not_active Application Discontinuation
- 2008-12-29 HK HK08114022.5A patent/HK1123036A1/xx not_active IP Right Cessation
-
2011
- 2011-06-15 US US13/161,003 patent/US8796458B2/en not_active Expired - Fee Related
- 2011-11-14 HR HR20110839T patent/HRP20110839T1/hr unknown
- 2011-11-24 CY CY20111101153T patent/CY1112085T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR054799A1 (es) | Derivados de oxindol | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20070141A1 (es) | Derivados de isoquinolina como inhibidores de rho-cinasa | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
PE20091689A1 (es) | DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1 | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
PE20081447A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
PE20060957A1 (es) | Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |